Roquefort Therapeutics hail LYRAMID identifying lead compounds to
Roquefort Therapeutics PLC (LSE:ROQ) chairman Stephen West talks to Proactive London about LYRAMID, their research and development subsidiary which has identified lead compounds that it will take forward for lab-based experiments to test their efficacy in altering cancer cell properties.
Midkine is a growth factor that is thought to play a key role in disease development, further work is currently being carried out to gather more data on the ability of these candidate drugs to modify midkine expression.
LYRAMID is exploring the use of midkine inhibitors to reverse the resistance to cancer immunotherapy drugs such as checkpoint inhibitors.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…
Read More: Roquefort Therapeutics hail LYRAMID identifying lead compounds to